Previsión
| Comprar |
3 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Zealand Pharma: Petrelintide reaches primary endpoint in phase-2 study
Zealand Pharma reports that Petrelintide met the primary endpoint in the phase-2 study Zupreme-2. Weekly subcutaneous injections resulted in a statistically significant and clinically meaningful weight loss versus placebo in all three treatment groups after 28 weeks. Together with Roche, Zealand is initiating a phase-3a program consisting of Zupreme-3, Zupreme-4 and Zupreme-5. » Más en finanzen.net
Zealand Pharma sells Rusfertide royalties to Royalty Pharma for $100 million
Zealand Pharma has sold its economic rights to Rusfertide to Royalty Pharma for $100 million. The payment is made in two tranches: $50 million at closing and $50 million on the first anniversary; the transaction is complete. Zealand retains a residual royalty of 0.25% on annual worldwide net sales above $1.5 billion, and Royalty Pharma receives 0.75% above that threshold. The FDA has set a target date for the approval application in the third quarter of 2026, and Takeda will take over worldwide commercialization. » Más en de.investing.com
Jefferies downgrade pushes Zealand Pharma shares lower
Jefferies downgraded Zealand Pharma from "Buy" to "Hold" and cut the price target from 505 DKK to 320 DKK, a decline of about 37%. The analyst house cited a lack of near‑term catalysts and reduced the success probability for survodutide from 60% to 40% due to ongoing tolerability concerns after Phase III data. With no company‑specific news, the downgrade was the main driver of the share drop; a short‑term recovery now depends largely on progress with petrelintide. » Más en de.investing.com
Zealand Pharma recovers after stock slump over study data
Zealand Pharma's shares rose about 6.8% today, partially reversing a more than 24% decline after negative study results. The Phase‑III trial of Survodutid showed high discontinuation rates due to gastrointestinal side effects, and Phase‑II data for Petrelintid showed only around 9% placebo‑adjusted weight loss, prompting Barclays to voice safety concerns. The stabilization today is attributed to the announced appearance of the CEO at the Goldman Sachs conference and an ongoing share buyback program (up to DKK 1.3bn). A fundamental turnaround in the clinical outlook is not signaled; the stock remains well below its 52‑week high. » Más en de.investing.com
Zealand Pharma shares plunge after mixed survodutide data from Boehringer
Boehringer Ingelheim published phase‑III data on survodutide showing strong weight loss and substantial reduction of liver fat, but high discontinuation rates due to side effects. As Boehringer’s partner, Zealand Pharma lost up to about 25% in Copenhagen at one point, wiping out roughly $900 million in market value. Boehringer sees medical potential but plans further studies with more flexible dosing; in the highest‑dose group nearly a quarter of patients discontinued treatment, with an overall discontinuation rate of 19% versus 2.9% in the placebo group. Experts highlight opportunities particularly for MASLD patients, while the market for obesity drugs is expected to be very large by 2030/the 2030s. » Más en n-tv.de
Datos financieros
En el último trimestre, Zealand Pharma Aktie tuvo unos ingresos de 535,08 mil € y un beneficio neto de -7,22 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 535,08 mil | 91,94 % |
| Beneficio bruto | 535,08 mil | 90,57 % |
| Beneficio neto | -7,22 M | 86,66 % |
| EBITDA | 2,27 M | 104,82 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1886,72 M € |
Número de acciones | 66,33 M |
Máximo/mínimo de 52 semanas | 74,35 € - 28,44 € |
| Dividendos | No |
Beta | 0,61 |
Ratio P/E | 4,84 |
Ratio PEG | -0,09 |
Ratio P/B | 0,87 |
Ratio P/S | 3,07 |
Perfil de la empresa
Zealand Pharma A/S, una empresa de biotecnología, se dedica al descubrimiento, desarrollo y comercialización de medicamentos basados en péptidos en Dinamarca. Cuenta con una cartera de medicamentos centrada en enfermedades gastrointestinales y metabólicas, y en otras áreas de enfermedades especializadas con necesidades médicas no cubiertas. La compañía comercializa lixisenatida con los nombres de marca Adlyxin y Lyxumia; dasiglucagón, una jeringa o autoinyector de un solo uso para el tratamiento de la hipoglucemia grave, el hiperinsulinismo congénito y la hipoglucemia posterior a la cirugía bariátrica; y el páncreas artificial de doble hormona con dasiglucagón para la gestión automatizada de la diabetes. La cartera de desarrollo de la compañía incluye dasiglucagón, que se encuentra en ensayos clínicos de fase III para el hiperinsulinismo congénito. La compañía también desarrolla glepaglutida, un análogo de GLP-2 de acción prolongada, que se encuentra en ensayos clínicos de fase III para el tratamiento del síndrome del intestino corto. Zealand Pharma A/S tiene acuerdos de colaboración con Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; y Beta Bionics, Inc. La compañía se constituyó en 1998 y tiene su sede en Copenhague, Dinamarca.
| Nombre | Zealand Pharma Aktie |
| CEO | Adam Sinding Steensberg |
| Sede | Søborg,
Dinamarca |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Salida a bolsa | 23/11/2010 |
| Empleados | 605 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Pnk | ZLDPF |
Nasdaq Copenhagen | ZEAL.CO |
Copenhagen | ZEAL.CO |
Frankfurt | 22Z.F |
Düsseldorf | 22Z.DU |
London | 0NZU.L |
München | 22Z.MU |
SIX | ZEAL.SW |